



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Fraxinellone

<b>Cat. No.:</b>	HY-N0242												
<b>CAS No.:</b>	28808-62-0												
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>16</sub> O <sub>3</sub>												
<b>Molecular Weight:</b>	232.28												
<b>Target:</b>	PD-1/PD-L1; HIF/HIF Prolyl-Hydroxylase; STAT												
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease; JAK/STAT Signaling; Stem Cell/Wnt												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (430.51 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	4.3051 mL	21.5257 mL	43.0515 mL
		5 mM	0.8610 mL	4.3051 mL	8.6103 mL
		10 mM	0.4305 mL	2.1526 mL	4.3051 mL
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Fraxinellone is isolated from the root bark of the Rutaceae plant, <i>Dictamnus dasycarpus</i> . Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 <sup>[1]</sup> .
<b>In Vitro</b>	Fraxinellone (0-100 μM×12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>

	Cell Line:	A549 cells
	Concentration:	0 $\mu$ M, 10 $\mu$ M, 30 $\mu$ M, 100 $\mu$ M
	Incubation Time:	12 hours
	Result:	Inhibited the percent of PD-L1 positive cells.
<b>In Vivo</b>	Fraxinellone (oral gavage; 30 and 100 mg/kg; every three days; 30 days) significantly suppresses tumor growth, reduces HIF-1 $\alpha$ , pTyr705 STAT3, PD-L1 and VEGF staining compared with the control group in female athymic BALB/c nude mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	BALB/c nude mice <sup>[1]</sup>
	Dosage:	30 and 100 mg/kg
	Administration:	Oral gavage; 30 and 100 mg/kg; every three days; 30 days
	Result:	Significantly suppressed tumor growth.

## CUSTOMER VALIDATION

- Biomed Pharmacother. September 2022, 113416.
- Int Immunopharmacol. 2024 May 21:135:112298.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1 $\alpha$  and STAT3. Pharmacol Res. 2018 Sep;135:166-180.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA